France's BioMerieux has acquired a 10 percent stake in Knome for $5 million and struck a deal to use the Cambridge, MA-based company's genome sequencing and analysis services. "The deal with Knome allows the group to strengthen its position in molecular biology and to create diagnostic tools for tomorrow," CM-CIC Securities analyst Arsene Guekam said in a research note. Story